Steven B. Hedlund, Chairman, President and CEO of Lincoln Electric Holdings Inc, filed a Form 4 on November 2, 2026, disclosing the exercise of two employee stock option tranches and the sale of 14,371 common shares on October 30, 2026.
Kim Kelderman, Chief Executive Officer and Director of BIO-TECHNE Corp, filed an amended statement of changes in beneficial ownership on November 2, 2026, covering multiple transactions in common stock, performance stock options, performance restricted stock units, and restricted stock units dated August 15, 2026.
A Statement of Changes in Beneficial Ownership for FiscalNote Holdings, Inc. was filed on November 2, 2026, covering a transaction dated October 29, 2026, by reporting person Key Compton, who serves as President and CEO and as a Director of the company.
Director Ron Mayron filed a Form 4 with the SEC on November 2, 2026, reporting the acquisition of 166,577 restricted share units in IceCure Medical Ltd., listed on NASDAQ:ICCM, following shareholder approval of the grant on that same date.
IceCure Medical Ltd. Chief Executive Officer and Director Eyal Shamir filed a Form 4 on November 2, 2026, disclosing the acquisition of 404,901 restricted share units granted on August 11, 2026.
Paul Kolodziej, CFO and Treasurer of Blackstone Real Estate Income Trust, Inc., filed a Form 4 on November 2, 2026, disclosing a purchase of Class I Common Stock on that same date.
ProPetro Holding Corp. Chief Financial Officer Caleb Lyle Weatherl filed a Form 4 on November 2, 2026, reporting the open-market purchase of 2,000 shares of common stock on October 30, 2026.
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corporation, filed a Form 4 on November 2, 2026, reporting the exercise of 9,500 stock options and the subsequent sale of the resulting common shares on October 30, 2026, pursuant to a pre-arranged 10b5-1 trading …
Director Robert V. Baumgartner filed a Form 4 with the SEC on November 2, 2026, disclosing the acquisition of 2,750 shares of BIO-TECHNE Corp common stock on October 29, 2026, along with a new stock option grant covering 3,777 shares.
Director Julie L. Bushman filed a Form 4 with the SEC on November 2, 2026, disclosing the acquisition of 2,750 shares of BIO-TECHNE Corp common stock on October 29, 2026, along with a new stock option grant on the same date.